Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "mutations"

123 News Found

AstraZeneca Pharma India receives approval for supplying Osimertinib in India
News | March 13, 2021

AstraZeneca Pharma India receives approval for supplying Osimertinib in India

The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.

Thermo Fisher’s new facility in Bengaluru to produce reliable COVID-19 testing kits
News | February 23, 2021

Thermo Fisher’s new facility in Bengaluru to produce reliable COVID-19 testing kits

Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.

Commercial disinfectants equally as effective against new COVID strains: CBC
News | January 13, 2021

Commercial disinfectants equally as effective against new COVID strains: CBC

Viruses evolve into new strains when there is a change to their genetic composition.

Latest Stories

Syngene International expands capabilities with new bioconjugation suite in Bengaluru

Quest Diagnostics reports strong third quarter 2025 results and raises full-year guidance

Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging